000790.SHE Chengdu Huasun Group Inc Ltd
- Market cap
- CNY 2.25B
- P/E
- -
- P/B
- 3.16x
- ROE
- -3.5%
- Dividend yield
- 0.59%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000790.SHE undervalued?
Graham numberThe Graham number of Chengdu Huasun Group Inc Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Huasun Group Inc Ltd fundamental analysis
No fundamental analysis for Chengdu Huasun Group Inc Ltd yet.
Chengdu Huasun Group Inc Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Huasun Group Inc Ltd
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs, as well as medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company des…
Full company profileChengdu Huasun Group Inc Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Huasun Group Inc Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 575M | 591M | 633M | 745M | 759M | 955M | 873M | 1.00B | 864M | 545M | 445M |
| Gross Profit | 315M | 309M | 416M | 464M | 403M | 383M | 349M | 394M | 433M | 260M | 180M |
| Operating Income | 104M | 225M | 43.3M | 75.9M | 47.4M | 64.3M | 39.2M | 29.0M | 4.76M | -93.2M | -12.9M |
| EBITDA | 142M | 256M | 68.6M | 92.0M | 60.1M | 82.9M | 77.9M | 78.1M | 60.3M | -279M | -15.6M |
| Net Income | 82.5M | 172M | 31.2M | 61.6M | 37.5M | 55.6M | 41.2M | 27.7M | -6.69M | -320M | -24.7M |
| EPS | 0.13 | 0.28 | 0.05 | 0.10 | 0.06 | 0.09 | 0.07 | 0.04 | -0.01 | -0.51 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.09B | 1.33B | 1.08B | 1.14B | 1.14B | 1.35B | 1.68B | 2.13B | 2.25B | 1.39B | 1.33B |
| Total Liabilities | 425M | 487M | 249M | 258M | 228M | 370M | 672M | 1.06B | 1.18B | 682M | 649M |
| Shareholders' Equity | 666M | 839M | 836M | 881M | 912M | 976M | 1.00B | 1.03B | 1.03B | 716M | 697M |
| Cash & Short-term Investments | 196M | 443M | 346M | 404M | 427M | 305M | 145M | 211M | 216M | 123M | 88.2M |
| Total Debt | 120M | 130M | 11.4M | 11.4M | 6.55M | 42.3M | 191M | 415M | 479M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 51.6M | -30.4M | 108M | 65.0M | 13.5M | -55.6M | 156M | 47.4M | 64.3M | 85.4M | - |
| Capital Expenditure | 4.00M | 6.35M | 11.2M | 1.49M | 2.52M | 113M | 165M | 189M | 142M | 63.0M | 32.7M |
| Free Cash Flow | 47.6M | -36.8M | 96.6M | 63.5M | 11.0M | -169M | -9.44M | -142M | -77.7M | 22.3M | -75.5M |
| Ratios | |||||||||||
| ROE | 12.4% | 20.5% | 3.7% | 7.0% | 4.1% | 5.7% | 4.1% | 2.7% | -0.7% | -44.8% | -3.5% |
| ROA | 7.6% | 12.9% | 2.9% | 5.4% | 3.3% | 4.1% | 2.5% | 1.3% | -0.3% | -23.1% | -1.9% |
| Net Profit Margin | 14.3% | 29.0% | 4.9% | 8.3% | 4.9% | 5.8% | 4.7% | 2.8% | -0.8% | -58.7% | -5.6% |
| Debt to Equity | 0.18x | 0.15x | 0.01x | 0.01x | 0.01x | 0.04x | 0.19x | 0.40x | 0.47x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chengdu Huasun Group Inc Ltd dividends
- Dividend yield
- 0.59%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 26, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 13.3M | 0.02 | - |
| 2024 | CNY 20.7M | 0.03 | - |
| 2023 | CNY 6.28M | 0.01 | 22.7% |
| 2022 | CNY 6.26M | 0.01 | 15.2% |
| 2021 | CNY 6.16M | 0.01 | 11.1% |
| 2020 | CNY 6.16M | 0.01 | 16.4% |
| 2019 | CNY 16.8M | 0.03 | 27.3% |
| 2018 | CNY 28.8M | 0.05 | 92.4% |
| 2017 | CNY 5.29M | 0.01 | 3.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on May 9, 2019.
Who owns Chengdu Huasun Group Inc Ltd
- Insiders 29.28%
- Institutions 1.18%
- Public & others 69.55%
- Shares outstanding 624M
- Free float 513M
Chengdu Huasun Group Inc Ltd company profile
- Company name
- Chengdu Huasun Group Inc Ltd
- Ticker
- 000790.SHE
- ISIN
- CNE0000001H5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jan 1, 1990
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 727
- Fiscal year end
- December
- Address
- No. 1168, Shuxin Avenue, Chengdu, China, 611731
- Phone
- 86 28 6769 2806
- Website
- huasungrp.com
About Chengdu Huasun Group Inc Ltd
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs, as well as medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu huasun technology group Inc. , LTD. in April 2020. The company was founded in 1988 and is based in Chengdu, China.
Chengdu Huasun Group Inc Ltd management
6- Mr. Mingliang HuangChairman & GM · born 1968
- Mr. Jun LiVP, Financial Director & Director · born 1980
- Ms. Ping OuyangVP & Non-Independent Director · born 1981
- Mr. Song GangVice President · born 1975
- Mr. Fang WanVice President
- Mr. Jian Hua LiVice President